Gambaran Umum
Cocrystal Pharma, Inc., based in the United States, operates in the biotechnology sector with a focus on discovering and developing novel antiviral therapeutics. The company leverages proprietary technology to design unique treatments targeting viral replication enzymes, addressing diseases such as influenza, coronavirus, and norovirus. As of 2023, Cocrystal Pharma has been actively developing broad-spectrum antiviral drugs, including candidates for COVID-19 and influenza. Key projects include the preclinical development of CC-42344, a potent influenza A polymerase inhibitor, and ongoing work on inhibitors targeting the replication machinery of coronaviruses, underscoring its commitment to addressing global antiviral drug resistance challenges through innovative pharmaceutical developments.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai operating income untuk Cocrystal Pharma, Inc. per 2025 Jun 30 adalah -12.72 MM.
- Nilai net income untuk Cocrystal Pharma, Inc. per 2025 Jun 30 adalah -12.56 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | -12.72 | -12.56 | |
2025-03-31 | -16.06 | -15.85 | |
2024-12-31 | -17.88 | -17.50 | |
2024-09-30 | -20.31 | -18.70 | |
2024-06-30 | -21.32 | -17.93 | |
2024-03-31 | -20.21 | -16.75 | |
2023-12-31 | -21.16 | -17.98 | |
2023-09-30 | -20.00 | -18.02 | |
2023-06-30 | -19.65 | -19.56 | |
2023-03-31 | -19.04 | -39.82 | |
2022-12-31 | -18.14 | -38.84 | |
2022-09-30 | -17.34 | -38.02 | |
2022-06-30 | -15.60 | -36.26 | |
2022-03-31 | -15.69 | -15.65 | |
2021-12-31 | -14.22 | -14.19 | |
2021-09-30 | 0.51 | -11.98 | -11.99 |
2021-06-30 | 1.00 | -10.74 | -10.72 |
2021-03-31 | 1.55 | -10.36 | -10.40 |
2020-12-31 | 2.01 | -9.59 | -9.65 |
2020-09-30 | 1.91 | -9.94 | -56.00 |
2020-06-30 | |||
2020-03-31 |
Laporan Laba Rugi: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | -1.84 | -1.84 |
2024-06-30 | -1.76 | -1.76 |
2024-03-31 | -1.65 | -1.65 |
2023-12-31 | -1.86 | |
2023-09-30 | -1.97 | -1.97 |
2023-06-30 | -2.27 | -2.27 |
2023-03-31 | -4.89 | -4.89 |
2022-12-31 | -4.77 | |
2022-09-30 | -4.67 | -4.67 |
2022-06-30 | -4.46 | -4.46 |
2022-03-31 | -1.98 | -1.98 |
2021-12-31 | -1.93 | |
2021-09-30 | -1.77 | -1.77 |
2021-06-30 | -1.80 | -1.80 |
2021-03-31 | -1.99 | -1.99 |
2020-12-31 | -2.10 | |
2020-09-30 | -14.51 | -14.51 |
2020-06-30 | -16.60 | -16.63 |
2020-03-31 | -18.38 | -18.40 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Cocrystal Pharma, Inc. per 2025 Jun 30 adalah -13.38 MM.
- Nilai cash from investing activities untuk Cocrystal Pharma, Inc. per 2025 Jun 30 adalah 0.00 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -13.38 | 0.00 | |
2025-03-31 | -14.92 | 0.00 | |
2024-12-31 | -16.48 | -0.01 | |
2024-09-30 | -16.65 | -0.07 | 0.00 |
2024-06-30 | -14.21 | -0.07 | 0.00 |
2024-03-31 | -16.06 | -0.08 | 4.00 |
2023-12-31 | -14.67 | -0.12 | 3.99 |
2023-09-30 | -16.23 | -0.07 | 3.99 |
2023-06-30 | -22.46 | -0.13 | 3.98 |
2023-03-31 | -20.64 | -0.12 | -0.03 |
2022-12-31 | -21.43 | -0.07 | -0.03 |
2022-09-30 | -19.46 | -0.07 | -0.03 |
2022-06-30 | -15.96 | -0.01 | -0.03 |
2022-03-31 | -14.86 | -0.03 | 36.40 |
2021-12-31 | -12.72 | -0.05 | 38.47 |
2021-09-30 | -12.18 | -0.04 | 42.09 |
2021-06-30 | -9.84 | -0.06 | 57.64 |
2021-03-31 | -9.41 | -0.17 | 21.18 |
2020-12-31 | -9.83 | -0.24 | 35.66 |
2020-09-30 | -8.68 | -0.24 | 34.71 |
2020-06-30 | |||
2020-03-31 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 | |||
2020-06-30 | |||
2020-03-31 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 | ||
2020-06-30 | ||
2020-03-31 |
Efektivitas Manajemen
- roa untuk Cocrystal Pharma, Inc. pada 2025 Jun 30 adalah -0.73.
- roe untuk Cocrystal Pharma, Inc. pada 2025 Jun 30 adalah -0.72.
- roic untuk Cocrystal Pharma, Inc. pada 2025 Jun 30 adalah -1.75.
- croic untuk Cocrystal Pharma, Inc. pada 2025 Jun 30 adalah -1.65.
- ocroic untuk Cocrystal Pharma, Inc. pada 2025 Jun 30 adalah -1.65.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.73 | -0.72 | -1.75 | -1.65 | -1.65 |
2025-03-31 | -0.70 | -0.70 | -1.28 | -1.15 | -1.14 |
2024-12-31 | -0.60 | -0.66 | -1.28 | -1.15 | -1.14 |
2024-09-30 | -0.57 | -0.61 | -0.94 | -0.74 | -0.74 |
2024-06-30 | -0.44 | -0.48 | -0.69 | -0.50 | -0.66 |
2024-03-31 | -0.44 | -0.45 | -0.58 | -0.40 | -0.53 |
2023-12-31 | -0.58 | -0.40 | -0.53 | ||
2023-09-30 | -0.37 | -0.40 | -0.56 | -0.53 | -0.64 |
2023-06-30 | -0.76 | -0.40 | -0.56 | -0.53 | -0.64 |
2023-03-31 | -0.54 | -1.14 | -0.60 | ||
2022-12-31 | 0.00 | ||||
2022-09-30 | -0.46 | -0.47 | -0.86 | -0.44 | -0.44 |
2022-06-30 | -0.41 | -0.43 | -0.73 | -0.32 | -0.32 |
2022-03-31 | -0.29 | -0.30 | -0.21 | 0.29 | -0.20 |
2021-12-31 | -0.26 | -0.27 | -0.18 | 0.33 | -0.16 |
2021-09-30 | -0.23 | -0.24 | -0.15 | 0.37 | -0.15 |
2021-06-30 | -0.26 | -0.29 | -0.13 | 0.56 | -0.12 |
2021-03-31 | -0.24 | -0.26 | -0.20 | 0.22 | -0.18 |
2020-12-31 | -0.34 | -0.38 | -0.18 | 0.48 | -0.19 |
2020-09-30 | -0.76 | -0.79 | -1.10 | 0.51 | -0.17 |
2020-06-30 | -0.74 | -0.76 | -1.46 | 0.31 | -0.18 |
2020-03-31 | -0.70 | -0.72 | -1.29 | 0.32 | -0.14 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | -18.78 | -30.70 | -30.76 |
2021-12-31 | -16.24 | -27.81 | -27.88 |
2021-09-30 | -13.63 | -23.52 | -23.50 |
2021-06-30 | -6.38 | -10.73 | -10.75 |
2021-03-31 | -3.07 | -6.69 | -6.67 |
2020-12-31 | -2.13 | -4.79 | -4.76 |
2020-09-30 | -2.30 | -29.38 | -5.22 |
2020-06-30 | -1.77 | -28.87 | -4.74 |
2020-03-31 | -1.26 | -27.29 | -3.67 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1412486 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |